

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE BY SECURED PARTY

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Silver Point Finance LLC		02/28/2006	LIMITED LIABILITY COMPANY: DELAWARE
Wachovia Bank, National Association		03/02/2006	National Association: UNITED STATES

RECEIVING PARTY DATA

Name:	AAIPharma Inc.
Street Address:	2320 Scientific Park Drive
City:	Wilmington
State/Country:	NORTH CAROLINA
Postal Code:	28405
Entity Type:	CORPORATION: DELAWARE

Name:	AAIPharma LLC
Street Address:	2320 Scientific Park Drive
City:	Wilmington
State/Country:	NORTH CAROLINA
Postal Code:	28405
Entity Type:	LIMITED LIABILITY COMPANY: DELAWARE

PROPERTY NUMBERS Total: 45

Property Type	Number	Word Mark
Registration Number:	1942885	AAI
Registration Number:	1647669	AAI
Registration Number:	1622884	APPLIED ANALYTICAL INDUSTRIES
Registration Number:	1946829	AAI
Registration Number:	2989410	AAI DEVELOPMENT SERVICES
Registration Number:	2346573	PROSORB

CH \$1140.00 1942885

Registration Number:	1033587	BRETHINE
Registration Number:	2723850	AAIPHARMA
Registration Number:	2715555	DEVELOPING CHEMISTRY INTO MEDICINE
Registration Number:	2647477	GLOBAL BIOANALYTICAL SOLUTIONS
Registration Number:	2716676	GLOBAL CLINICAL SOLUTIONS
Registration Number:	2650838	GLOBAL CMC SOLUTIONS
Registration Number:	2647476	GLOBAL PHARMACEUTIC SOLUTIONS
Registration Number:	2650837	GLOBAL REGULATORY SOLUTIONS
Registration Number:	2612966	PROCORE
Registration Number:	2672325	PROMELT
Registration Number:	2823015	PROSLO
Registration Number:	2672324	PROSPHER
Registration Number:	2747955	AZASAN
Registration Number:	2759076	WITHIN THE SCIENCE LIES THE MEDICINE THAT WILL CHANGE A LIFE
Registration Number:	1600106	PCL
Registration Number:	2805084	THE NEXT STEP DOESN'T HAVE TO BE BIG
Registration Number:	2874296	VANDOREN JAZZ
Serial Number:	78052057	AAICALC
Serial Number:	76186020	NEOSAN PHARMACEUTICALS
Serial Number:	78112668	BRANDS THAT MATTER MADE BETTER
Serial Number:	78112671	RESTORES BALANCE - EVERY DAY!
Serial Number:	78246168	AAIPHARMA ASSISTS
Serial Number:	78233839	AQUAJECT D
Serial Number:	78233837	AQUAJEX D
Serial Number:	78230629	BETWEEN NSAIDS AND CIII NARCOTICS
Serial Number:	78249649	AAI DEVELOPMENT SERVICES
Serial Number:	78233325	
Serial Number:	78216417	DOLOJEX
Serial Number:	78249415	GET IT RIGHT. ON TIME.
Serial Number:	78211699	METHAJEX
Serial Number:	78262905	PANDAJEX
Serial Number:	78245491	PROLONIC
Serial Number:	78196070	ZENIX
Serial Number:	78133903	PROSORB-D

Serial Number:	78278834	PROZOR
Serial Number:	78359257	IMPROVING MEDICINES THAT IMPROVE THE QUALITY OF LIFE
Serial Number:	78348249	LUCEVE
Serial Number:	78348247	PANQUELL
Serial Number:	78332238	PROLONICAQ

CORRESPONDENCE DATA

Fax Number: (212)822-5456
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
Phone: 212-530-5000
Email: fbruno@milbank.com
Correspondent Name: Frank A. Bruno
Address Line 1: 1 Chase Manhattan Plaza
Address Line 2: Milbank, Tweed, Hadley & McCloy LLP
Address Line 4: New York, NEW YORK 10005-1413

ATTORNEY DOCKET NUMBER:	38535-00200
NAME OF SUBMITTER:	Frank A. Bruno
Signature:	/FAB/
Date:	03/07/2006

Total Attachments: 9
source=38535-00200 Release of Security Interest in US patents and patent applications_v7_#page1.tif
source=38535-00200 Release of Security Interest in US patents and patent applications_v7_#page2.tif
source=38535-00200 Release of Security Interest in US patents and patent applications_v7_#page3.tif
source=38535-00200 Release of Security Interest in US patents and patent applications_v7_#page4.tif
source=38535-00200 Release of Security Interest in US patents and patent applications_v7_#page5.tif
source=38535-00200 Release of Security Interest in US patents and patent applications_v7_#page6.tif
source=38535-00200 Release of Security Interest in US patents and patent applications_v7_#page7.tif
source=38535-00200 Release of Security Interest in US patents and patent applications_v7_#page8.tif
source=38535-00200 Release of Security Interest in US patents and patent applications_v7_#page9.tif

RELEASE OF SECURITY INTEREST IN UNITED STATES COPYRIGHTS,
TRADEMARKS AND PATENTS

Silver Point Finance LLC
600 Steamboat Road
Greenwich, Connecticut 06830
("Silver Point")

Wachovia Bank, National Association, as Collateral Agent
401 South Tryon Street
Charlotte, North Carolina 28288-1179
("Wachovia")

WHEREAS, Silver Point is the Collateral Agent and Wachovia is the Indenture Trustee and Collateral Agent with respect to certain security interests pledged, assigned and granted for the benefit of the Senior Agents and the Lenders and the holders of the Notes, respectively, by AAIPharma Inc. and aaiPharma LLC (collectively the "Grantors") pursuant to the Security Agreement dated as of April 23, 2004 (as amended or supplemented, the "Security Agreement");

WHEREAS, the security offered by the Grantors includes in part the copyrights, trademarks and patents, along with any applications therefor listed on the attached Schedule I (the "Released United States Copyright, Trademark and Patent Collateral");

WHEREAS, the security interests held by Silver Point in the Released United States Copyright, Trademark and Patent Collateral for AAIPharma Inc. and aaiPharma LLC were recorded in the United States Patent and Trademark Office on April 30, 2004, at Reel 014580 Frame 0798 (patents) and at Reel 002845 Frame 0756 (trademarks);


WHEREAS, Grantors have confirmed that the security interests held by Wachovia in the Released United States Copyright, Trademark and Patent Collateral for AAIPharma Inc. were recorded in the United States Patent and Trademark Office for patents on May 12, 2004, at Reel 014615 Frame 0837, on December 28, 2005 at Reel 016946 Frame 0712, and on April 19, 2005 at Reel 015919 Frame 0947; and for trademarks on May 12, 2004 at Reel 002854 Frame 0704, and on September 13, 2004 at Reel 002937 Frame 0277;

WHEREAS, terms defined in the Security Agreement are used herein as defined therein;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each of Silver Point and Wachovia does hereby release and terminate its entire right, title and interest in and to the Released United States Copyright, Trademark and Patent Collateral, and authorizes the recordation of this Release Of Security Interest In United States Copyrights, Trademarks and Patents in the United States Patent and Trademark Office forthwith.

Date: February 28, 2006

Silver Point Finance LLC,
as Collateral Agent

By: 
Name: **Frederick H. Fogel**
Title: **General Counsel**

STATE OF New York)
) SS.:
COUNTY OF New York)

On the 28th day of February, 2006, before me, the undersigned, a notary public in and for said state, personally appeared Frederick H. Fogel, personally known to me or proved to me on the basis of satisfactory evidence to be the individual whose name is subscribed to the within instrument, and acknowledged to me that he/she executed the same in his/her capacity and that by his/her signature on the instrument the individual or the person upon behalf of which the individual acted executed the instrument.




Notary Public

MICHAEL M. MEZZACAPPA
Notary Public, State of New York
No. 02ME6044324
Qualified in Richmond County
Commission Expires July 3, 2006

[SEAL]


Date: March 2, 2006

Wachovia Bank, National Association,
as Collateral Agent


By: 
Name: Charles S. Hodges
Title: Vice President

STATE OF North Carolina
COUNTY OF Mecklenburg) SS.:

On the 2 day of March, 2006, before me, the undersigned, a notary public in and for said state, personally appeared Charles S. Hodges personally known to me or proved to me on the basis of satisfactory evidence to be the individual whose name is subscribed to the within instrument, and acknowledged to me that he/she executed the same in his/her capacity and that by his/her signature on the instrument the individual or the person upon behalf of which the individual acted executed the instrument.


Notary Public

[SEAL]



Release of IP Security Interest

Schedule I

1. U.S. Registered Trademarks

Trademark Name	Registration Number	Date
AAI (design plus words)*	1,942,885	December 19, 1995
AAI (typed drawing)*	1,647,669	June 11, 1991
Applied Analytical Industries (typed drawing)*	1,622,884	November 13, 1990
AAI (Design)*	1,946,829	January 9, 1996
AAI Development Services	2,989,410	August 30, 2005
PROSORB*	2,346,573	May 2, 2000
BRETHINE**	1,033,587	February 7, 1976
aaiPharma*	2,723,850	June 10, 2003
DEVELOPING CHEMISTRY INTO MEDICINE*	2,715,555	May 13, 2003
GLOBAL BIOANALYTICAL SOLUTIONS*	2,647,477	November 5, 2002
GLOBAL CLINICAL SOLUTIONS*	2,716,676	May 13, 2003
GLOBAL CMC SOLUTIONS*	2,650,838	November 12, 2002
GLOBAL PHARMACEUTIC SOLUTIONS*	2,647,476	November 5, 2002
GLOBAL REGULATORY SOLUTIONS*	2,650,837	November 12, 2002
PROCORE*	2,612,966	August 27, 2002
PROMELT*	2,672,325	January 7, 2003
PROSLO	2,823,015	March 16, 2004
PROSPHER*	2,672,324	January 7, 2003
AZASAN*	2,747,955	August 5, 2003
WITHIN THE SCIENCE LIES THE MEDICINE THAT WILL CHANGE A LIFE*	2,759,076	September 2, 2003
PCL*	1,600,106	June 5, 1990
THE NEXT STEP DOESN'T HAVE TO BE SO BIG**	2,805,084	January 13, 2004
NEOSAN "O" DESIGN*	2,874,296	November 18, 2003

* owned by AAIPharma Inc.

** owned by aaiPharma LLC

2. U.S. Trademark Applications

Trademark Name	Pending Trademarks Application Number	Date
aaiCalc*	78/052,057	March 8, 2001
NEOSAN PHARMACEUTICALS AND DESIGN*	76/186,020	December 20, 2000
BRANDS THAT MATTER MADE BETTER**	78/112,668	March 5, 2002
RESTORES BALANCE – EVERY DAY!***	78/112,671	March 5, 2002
aaiPharma assists*	78/246,168	May 6, 2003
AQUAJECT D*	78/233,839	April 4, 2003
AQUAJEX D*	78/233,837	April 4, 2003
BETWEEN NSAIDS AND CIII NARCOTICS**	78/230,629	March 27, 2003
Design of stylized AAI with Swoosh*	78/249,649	May 14, 2003
DIAMOND SHAPE AND CURVED LINE LOGO*	78/233,325	April 3, 2003
DOLOJEX*	78/216,417	February 19, 2003
GET IT RIGHT. ON TIME.*	78/249,415	May 14, 2003
METHAJEX*	78/211,699	February 6, 2003
PANDAJEX*	78/262,905	June 16, 2003
ProLonic*	78/245,491	May 5, 2003
ZENIX*	78/196,070	December 19, 2002
PROSORB-D*	78/133,903	June 7, 2002
PROZOR*	78/278,834	July 25, 2003
IMPROVING MEDICINES THAT IMPROVE THE QUALITY OF LIFE*	78/359,257	January 29, 2004
LUCEVE*	78/348,249	January 6, 2004
PANQUELL*	78/348,247	January 6, 2004
PROLONIC AQ*	78/332,238	November 24, 2003

3. U.S. Patents

Title	Registration Number	Date
Dry blend pharmaceutical formulations Omeprazole*	6,268,385	July 31, 2001
Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same*	6,262,085	July 17, 2001
Pharmaceutical unit dosage form Omeprazole*	6,262,086	July 17, 2001

* owned by AAIPharma Inc.

** owned by aaiPharma LLC

Title	Registration Number	Date
Form A of fluoxetine hydrochloride*	6,258,853	July 10, 2001
Oral Liquid Pharmaceutical Compositions of Sulindac*	4,880,835	November 14, 1989
Liquid Oral Pharmaceutical Compositions of Non-Steroidal Anti-Inflammatory Drugs ProSorb*	5,183,829	February 2, 1993
Oral Compositions of Proteinaceous Medicaments*	5,206,219	April 27, 1993
Oral Compositions of H ₂ -Antagonists*	5,622,980	April 22, 1997
Oral Compositions of H ₂ - Antagonists*	5,538,737	July 23, 1996
Pharmaceutical Grinding Apparatus and Method for Using Same*	5,733,173	March 31, 1998
Spray drying of pharmaceutical formulations containing amino acid-based materials*	5,902,844	May 11, 1999
Liquid Oral Pharmaceutical Compositions of Non-Steroidal Anti-Inflammatory Drugs*	4,918,103	April 17, 1990
Liquid Oral Pharmaceutical Compositions of Non-Steroidal Anti-Inflammatory Drugs*	5,011,852	April 30, 1991
Pharmaceutical Formulations Omeprazole*	6,316,020	November 13, 2001
Method of Improving Bioavailability Omeprazole*	6,312,712	November 6, 2001
Pharmaceutical Unit Dosage Form Omeprazole*	6,312,723	November 13, 2001
Dry Blend Pharmaceutical Unit Dosage Form Omeprazole*	6,326,384	December 4, 2001
Form A of Fluoxetine Hydrochloride*	6,316,672	November 13, 2001
Form A of Fluoxetine Hydrochloride*	6,313,350	November 6, 2001
Form A of Fluoxetine Hydrochloride*	6,310,251	October 30, 2001
Form A of Fluoxetine Hydrochloride*	6,310,250	October 30, 2001
Oral Liquid Compositions ProSorb®II*	6,287,594	September 11, 2001
Stable Calcitriol Solution for Packaging into Vials*	6,211,169	April 3, 2001
Controlled Release Delivery Coating Formulation for Bioactive Substances*	4,891,223	January 2, 1990
Polymorphic Forms of 6-[4-(1-CYCLOHEXYL-1H-TETRAZOL-5-YL)BUTOXY]-3,4-DIHYDRO-2(1H)-QUINOLINONE (Cilostazol)*	6,573,382	June 3, 2003
Polymorphic Forms of 6-[4-(1-CYCLOHEXYL-1H-TETRAZOL-5-YL)BUTOXY]-3,4-DIHYDRO-2(1H)-QUINOLINONE (Cilostazol)*	6,531,603	March 11, 2003
Form A of Fluoxetine Hydrochloride*	6,492,556	December 10, 2002
Alkoxy Substituted Benzimidazole Compounds, Pharmaceutical Preparations Containing the Same, and Methods Using the	6,444,689	September 3, 2002

* owned by AAIPharma Inc.

** owned by aaiPharma LLC

Title	Registration Number	Date
Same*		
Polymorphic Forms of 6-[4-(1-CYCLOHEXYL-1H-TETRAZOL-5-YL)BUTOXY]-3,4-DIHYDRO-2(1H)-QUINOLINONE (Cilostazol)*	6,388,080	May 14, 2002
Alkoxy Substituted Benzimidazole Compounds, Pharmaceutical Preparations Containing the Same, and Methods Using the Same Omeprazole*	6,369,087	April 9, 2002
Oral Liquid Compositions ProSorb® II*	6,365,180	April 2, 2002
Process for Purifying 6-methoxy Omeprazole*	6,608,091	August 19, 2003
Polymorphic Forms of 6-[4-(1-CYCLOHEXYL-1H-TETROZOL-5-YL)BUTOXY]-3,4-DIHYDRO-2(1H)-QUINOLINONE (Cilostazol)*	6,596,871	July 22, 2003
Alkoxy Substituted Benzimidazole Compounds, Pharmaceutical Preparations Containing the Same, and Methods Using the Same*	6706737	March 16, 2004
DRY BLEND PHARMACEUTICAL FORMULATIONS*	6667324	December 23, 2003
DRY BLEND PHARMACEUTICAL FORMULATIONS*	6667323	December 23, 2003
Process for Purifying Omeprazole*	6,673,936	January 6, 2004
Polymorphic Forms of 6-[4-(1-CYCLOHEXYL-1H-TETROZOL-5-YL)BUTOXY]-3,4-DIHYDRO-2(1H)-QUINOLINONE (Cilostazol)*	6,657,061	December 2, 2003
Polymorphic Forms of 6-[4-(1-CYCLOHEXYL-1H-TETROZOL-5-YL)BUTOXY]-3,4-DIHYDRO-2(1H)-QUINOLINONE (Cilostazol)*	6,660,864	December 9, 2003
GRANULATED PHARMACEUTICAL FORMULATIONS AND METHODS FOR MAKING THE SAME*	6,653,329	May 16, 2003
Alkoxy Substituted Benzimidazole Compounds, Pharmaceutical Preparations Containing the Same, and Methods Using the Same*	6,667,321	December 23, 2003

4. U.S. Patent Applications

Title	Pending Application Number	Date
Pharmaceutical Formulations	Not yet available	January 30, 2004
Narcotic-NSAID Ion Pairs	10/796,308	March 10, 2004

* owned by AAIPharma Inc.

** owned by aaiPharma LLC

Title	Pending Application Number	Date
FT-Raman Spectroscopic Measurement*	09/649,447	August 25, 2000
FT-Raman Spectroscopic Measurement*	09/648,490	August 25, 2000
FT-Raman Spectroscopic Measurement*	09/648,497	August 25, 2000
Form A of Fluoxetine Hydrochloride*	09/772,991	January 31, 2001
Process for Purifying Omeprazole*	09/839,395	April 20, 2001
Polymorphic Forms of 6-[4-(1-CYCLOHEXYL-1H-TETROZOL-5-YL) BUTOXY]-3,4-DIHYDRO-2(1H)-QUINOLINONE (Cilostazol)*	09/896,449	June 29, 2001
Polymorphic Forms of 6-[4-(1-CYCLOHEXYL-1H-TETROZOL-5-YL) BUTOXY]-3,4-DIHYDRO-2(1H)-QUINOLINONE (Cilostazol)*	09/896,185	June 29, 2001
POLYMORPHIC FORMS OF 3-[2-[4-(6-FLUORO-1,2-BENZISOXANZOL-3-yl)-1-PIERIDINYL]ETHYL]-6,7,8,9-TETRAHYDRO-2-METHYL-4H-PYRIDO[1,2- α]PYRIMIDIN-4-ONE AND FORMULATIONS THEREOF (Risperidone)*	10/109,513	March 28, 2002
POLYMORPHIC FORMS OF 3-[2-[4-(6-FLUORO-1,2-BENZISOXANZOL-3-yl)-1-PIPERIDINYL]ETHYL]-6,7,8,9-TETRAHYDRO-2-METHYL-4H-PYRIDO[1,2- α]PYRIMIDIN-4-ONE AND FORMULATIONS THEREOF (Risperidone)*	10/109,086	March 28, 2002
POLYMORPHIC FORMS OF 3-[2-[4-(6-FLUORO-1,2-BENZISOXANZOL-3-yl)-1-PIPERIDINYL]ETHYL]-6,7,8,9-TETRAHYDRO-2-METHYL-4H-PYRIDO[1,2- α]PYRIMIDIN-4-ONE AND FORMULATIONS THEREOF (Risperidone)*	10/108,729	March 28, 2002
POLYETHER BREVETOXIN DERIVATIVES AS A TREATMENT FOR NEUROTOXIC SHELLFISH POISONING AND CIGUATERA FISH POISONING (UNCW)*	60/504,670	September 19, 2003
POLYETHER BREVETOXIN DERIVATIVES AS A TREATMENT FOR CYSTIC FIBROSIS, MUCOCILIARY DYSFUNCTION, AND PULMONARY DISEASES (UNCW)*	60/504,665	September 19, 2003
POLYETHER BREVENAL AND DERIVATIVES THEREOF USEFUL FOR THE TREATMENT FOR PULMONARY DISEASES ASSOCIATED WITH MUCOCILIARY DYSFUNCTION AND BREVETOXIN AND CIGUATOXIN POISONING (UNCW)*	60/504,669	September 19, 2003
METHOD OF REDUCING THE RISK OF ADVERSE CARDIOVASCULAR EVENTS*	60/499,153	August 29, 2003

Title	Pending Application Number	Date
GRANULATED PHARMACEUTICAL FORMULATIONS AND METHODS FOR MAKING THE SAME*	10/439,865	May 16, 2003
FORM A OF FLUOXETINE HYDROCHLORIDE*	10/136,582	May 1, 2002
METHOD OF REDUCING THE RISK OF OXIDATIVE STRESS	60/499,153 2004927790	August 29, 2003 August 27, 2004
MAGNESIUM COMPLEXES OF S- OMEPRAZOLE	10/855,809	May 28, 2004
METHOD OF TREATING CANCER USING DITHIOCARBAMATE DERIVATIVES	10/922,728	August 20, 2004
FLEXIBLE SPINAL STABILIZATION SYSTEM AND METHOD***	10/793,308	March 4, 2004

5. The Companies have no registered U.S. copyrights.

NY2:#4675766

* owned by AAIPharma Inc.

** owned by aaiPharma LLC

*** Not now or previously owned by the Grantors. This patent application was likely confused with U.S. Patent App. Ser. No. 10/796,308 owned by AAIPharma Inc. and previously erroneously recorded against. It is listed and will be released as a correction.